Harmony Biosciences (HRMY) CFO granted 164,309 stock options at $29.29 strike

Rhea-AI Filing Summary

Harmony Biosciences Holdings, Inc. reported that Chief Financial Officer Glenn Reicin received a grant of stock options covering 164,309 shares of common stock. The options have an exercise price of $29.29 per share and expire on April 14, 2036.

According to the vesting terms, 25% of the underlying shares vest on April 14, 2027, with the remaining shares vesting quarterly until the fourth anniversary of the grant date, subject to his continued service. Following this award, Reicin holds 164,309 stock options directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Reicin Glenn

Role CHIEF FINANCIAL OFFICER

Type	Security	Shares	Price	Value
Grant/Award	Stock Option	164,309	$0.00	--

Holdings After Transaction: Stock Option — 164,309 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 164,309 options Exercise price: $29.29 per share Expiration date: April 14, 2036 +2 more

5 metrics

Options granted 164,309 options Stock option grant to CFO Glenn Reicin

Exercise price $29.29 per share Stock option exercise price

Expiration date April 14, 2036 Option term end date

Post-transaction options held 164,309 options Total derivative holdings after grant

Initial vesting tranche 25% of underlying shares Vesting on April 14, 2027

Key Terms

Stock Option, exercise price, Grant, award, or other acquisition, vesting

4 terms

Stock Option financial

"The stock option vests with respect to 25% of the underlying shares"

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

exercise price financial

"conversion_or_exercise_price: "29.2900""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

vesting financial

"with the remaining shares vesting ratably on a quarterly basis"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Reicin Glenn

(Last) (First) (Middle)

C/O HARMONY BIOSCIENCES HOLDINGS, INC.

(Street)

PLYMOUTH MEETING PENNSYLVANIA 19462

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Harmony Biosciences Holdings, Inc. [ HRMY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF FINANCIAL OFFICER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$29.29	04/14/2026		A		164,309		(1)	04/14/2036	Common Stock	164,309	$0	164,309	D

Explanation of Responses:

1. The stock option vests with respect to 25% of the underlying shares on April 14, 2027, with the remaining shares vesting ratably on a quarterly basis thereafter until the fourth anniversary of the grant date, subject to the Reporting Person's continued service through each applicable vesting date.

	/s/ Christian Ulrich, Attorney-in-Fact	05/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Harmony Biosciences (HRMY) report for Glenn Reicin?

Harmony Biosciences reported that CFO Glenn Reicin received a stock option grant covering 164,309 shares of common stock. The award is a compensation-related grant, not an open-market share purchase or sale, and is documented as a derivative transaction on the Form 4 filing.

What are the key terms of Glenn Reicin’s Harmony Biosciences (HRMY) option grant?

The CFO received stock options on 164,309 underlying shares with an exercise price of $29.29 per share. These options are scheduled to expire on April 14, 2036, giving him a long-dated right to buy Harmony Biosciences common stock at that price.

How do Glenn Reicin’s Harmony Biosciences (HRMY) options vest over time?

The grant vests 25% of the underlying shares on April 14, 2027. The remaining 75% then vest ratably on a quarterly basis until the fourth anniversary of the grant date, contingent on his continued service with Harmony Biosciences through each vesting date.

Is Glenn Reicin’s Harmony Biosciences (HRMY) Form 4 transaction a stock purchase or sale?

The Form 4 reports a grant of stock options classified as an acquisition under code A, meaning a compensation-related award. It is not an open-market stock purchase or sale; instead, it gives him the right to buy shares later at a fixed exercise price.

What is Glenn Reicin’s reported Harmony Biosciences (HRMY) position after this option grant?

After the transaction, Glenn Reicin is shown as directly holding 164,309 stock options linked to Harmony Biosciences common stock. These options represent potential future share ownership, contingent on vesting and any exercises he may choose to make at the stated exercise price.